2020 Q3 Form 10-Q Financial Statement

#000180136820000009 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q3
Revenue $41.02M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.100M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.179M
YoY Change
% of Gross Profit
Operating Expenses $3.100M
YoY Change
Operating Profit $16.15M
YoY Change
Interest Expense $1.713M
YoY Change
% of Operating Profit 10.6%
Other Income/Expense, Net $61.00K
YoY Change
Pretax Income $14.50M
YoY Change
Income Tax -$125.0K
% Of Pretax Income -0.86%
Net Earnings $14.63M
YoY Change
Net Earnings / Revenue 35.66%
Basic Earnings Per Share $0.20
Diluted Earnings Per Share $0.20
COMMON SHARES
Basic Shares Outstanding 71.94M shares
Diluted Shares Outstanding 71.94M shares

Balance Sheet

Concept 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $900.0K
YoY Change
Cash & Equivalents $30.24M
Short-Term Investments
Other Short-Term Assets $300.0K
YoY Change
Inventory
Prepaid Expenses $334.5K
Receivables
Other Receivables
Total Short-Term Assets $1.243M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $345.1M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $345.1M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.243M
Total Long-Term Assets $345.1M
Total Assets $346.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.400M
YoY Change
Accrued Expenses $100.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.533M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $12.10M
YoY Change
Total Long-Term Liabilities $12.10M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.533M
Total Long-Term Liabilities $12.10M
Total Liabilities $15.61M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$3.389M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.12M
YoY Change
Total Liabilities & Shareholders Equity $346.3M
YoY Change

Cashflow Statement

Concept 2020 Q3
OPERATING ACTIVITIES
Net Income $14.63M
YoY Change
Depreciation, Depletion And Amortization $2.179M
YoY Change
Cash From Operating Activities -$480.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -40.00K
YoY Change
NET CHANGE
Cash From Operating Activities -480.0K
Cash From Investing Activities 0.000
Cash From Financing Activities -40.00K
Net Change In Cash -520.0K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$480.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001801368
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 fvac Number Of Redeemable Warrants In Each Unit Issued In Public Offering
NumberOfRedeemableWarrantsInEachUnitIssuedInPublicOffering
0.3333 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39277
dei Entity Registrant Name
EntityRegistrantName
FORTRESS VALUE ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4465489
dei Entity Address Address Line1
EntityAddressAddressLine1
1345 Avenue of the Americas
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10105
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
798-6100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2020Q3 us-gaap Cash
Cash
909007 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
334489 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1243496 USD
CY2020Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
345068821 USD
CY2020Q3 us-gaap Assets
Assets
346312317 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3396213 USD
CY2020Q3 fvac Franchise Tax Payable Current
FranchiseTaxPayableCurrent
137046 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3533259 USD
CY2020Q3 fvac Deferred Underwriting Commissions Payable
DeferredUnderwritingCommissionsPayable
12075000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
15608259 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8387826 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3388874 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5000008 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
346312317 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3048747 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3320649 USD
CY2020Q3 fvac Franchise Tax Expense
FranchiseTaxExpense
50232 USD
fvac Franchise Tax Expense
FranchiseTaxExpense
137046 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3098979 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3457695 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
31946 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
68821 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3067033 USD
us-gaap Net Income Loss
NetIncomeLoss
-3388874 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5500 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
19500 USD
CY2020Q2 fvac Sale Of Units In Initial Public Offering Net Of Offering Costs Par Value
SaleOfUnitsInInitialPublicOfferingNetOfOfferingCostsParValue
325167932 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
8900000 USD
CY2020Q2 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-328771090 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-316341 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5000001 USD
CY2020Q3 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3067040 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3067033 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5000008 USD
us-gaap Net Income Loss
NetIncomeLoss
-3388874 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
68821 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
334489 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2785762 USD
fvac Increase Decrease In Franchise Tax Payable
IncreaseDecreaseInFranchiseTaxPayable
137046 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-869376 USD
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
345000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-345000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
211382 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
211382 USD
fvac Proceeds From Issuance Initial Public Offering Net Of Underwriting Commission
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingCommission
338100000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
246617 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8900000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
346778383 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
909007 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
909007 USD
fvac Offering Costs Accounts Payable And Accrued Expenses Noncash
OfferingCostsAccountsPayableAndAccruedExpensesNoncash
610451 USD
fvac Deferred Offering Costs Noncash Financing Activities
DeferredOfferingCostsNoncashFinancingActivities
12075000 USD
us-gaap Stock Issued1
StockIssued1
325704050 USD
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
345000000.0 USD
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
19800000 USD
CY2020Q2 fvac Deferred Underwriting Commissions Payable
DeferredUnderwritingCommissionsPayable
12100000 USD
CY2020Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8900000 USD
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
345000000.0 USD
CY2020Q2 fvac Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P185D
CY2020Q3 us-gaap Cash
Cash
900000 USD
CY2020Q3 fvac Minimum Percentage Of Fair Market Value Of Business Acquisition To Trust Account Balance
MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance
0.80
CY2020Q3 fvac Minimum Percentage Of Voting Interests To Be Acquired In Business Combination
MinimumPercentageOfVotingInterestsToBeAcquiredInBusinessCombination
0.50
CY2020Q3 fvac Minimum Net Tangible Assets To Complete Business Combination
MinimumNetTangibleAssetsToCompleteBusinessCombination
5000001 USD
CY2020Q3 fvac Minimum Net Tangible Assets To Complete Business Combination
MinimumNetTangibleAssetsToCompleteBusinessCombination
5000001 USD
CY2020Q3 fvac Percentage Of Public Shares Required To Repurchase If Business Combination Is Not Completed Within Specific Period
PercentageOfPublicSharesRequiredToRepurchaseIfBusinessCombinationIsNotCompletedWithinSpecificPeriod
1
fvac Number Of Fractional Warrants Be Issued
NumberOfFractionalWarrantsBeIssued
0 shares
CY2020Q3 us-gaap Cash
Cash
900000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
68821 USD
CY2020Q3 fvac Working Capital Deficiency
WorkingCapitalDeficiency
2300000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed as of September 30, 2020, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></div>
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
19800000 USD
CY2020Q2 fvac Deferred Underwriting Commissions Payable
DeferredUnderwritingCommissionsPayable
12100000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
31946 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
68821 USD
CY2020Q3 fvac Investment Income Interest Income Used To Pay Taxes
InvestmentIncomeInterestIncomeUsedToPayTaxes
31946 USD
fvac Investment Income Interest Income Used To Pay Taxes
InvestmentIncomeInterestIncomeUsedToPayTaxes
68821 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal depository insurance coverage of $250,000. As of September 30, 2020, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
CY2020Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2020Q2 fvac Number Of Shares In Each Unit
NumberOfSharesInEachUnit
1 shares
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 USD
fvac Common Stock Threshold Trading Days
CommonStockThresholdTradingDays
20 day
fvac Common Stock Threshold Consecutive Trading Days
CommonStockThresholdConsecutiveTradingDays
30 day
fvac Class Of Warrant Or Right Blackout Trading Period After Completion Of Business Combination
ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination
P30D
CY2020Q2 fvac Underwriting Agreement Option Period
UnderwritingAgreementOptionPeriod
P45D
CY2020Q2 fvac Underwriting Discount
UnderwritingDiscount
0.20
CY2020Q2 fvac Underwriting Discount Paid
UnderwritingDiscountPaid
6900000 USD
CY2020Q2 fvac Deferred Underwriting Discount
DeferredUnderwritingDiscount
0.35
CY2020Q2 fvac Deferred Underwriting Commissions Payable
DeferredUnderwritingCommissionsPayable
12100000 USD
CY2020Q3 fvac Class F Percentageof Total Common Stock Outstanding Upon Completionof Initial Public Offering
ClassFPercentageofTotalCommonStockOutstandingUponCompletionofInitialPublicOffering
0.20
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
fvac Warrants Exercise Period Following Business Combination
WarrantsExercisePeriodFollowingBusinessCombination
P30D
fvac Warrants Exercise Period Following Initial Public Offering
WarrantsExercisePeriodFollowingInitialPublicOffering
P12M
CY2020Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
fvac Restriction Period For Transfer Assignment Or Sale
RestrictionPeriodForTransferAssignmentOrSale
P30D
fvac Redemption Price Per Warrant
RedemptionPricePerWarrant
0.01
fvac Numberof Daysfor Written Noticeof Redemption
NumberofDaysforWrittenNoticeofRedemption
P30D
fvac Minimum Threshold Priceof Common Stock Specifiedto Send Noticeof Redemptiontothe Warrant Holders
MinimumThresholdPriceofCommonStockSpecifiedtoSendNoticeofRedemptiontotheWarrantHolders
18.00
fvac Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price
PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice
9.20
CY2020Q3 fvac Percentageof Warrant Exercise Price Adjustedto Price Receivedin New Issuance
PercentageofWarrantExercisePriceAdjustedtoPriceReceivedinNewIssuance
1.15

Files In Submission

Name View Source Status
0001801368-20-000009-index-headers.html Edgar Link pending
0001801368-20-000009-index.html Edgar Link pending
0001801368-20-000009.txt Edgar Link pending
0001801368-20-000009-xbrl.zip Edgar Link pending
exhibit311-10xqxfortre.htm Edgar Link pending
exhibit312-10xqxfortre.htm Edgar Link pending
exhibit321-10xqxfortre.htm Edgar Link pending
exhibit322-10xqxfortre.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fvac-20200930.htm Edgar Link pending
fvac-20200930.xsd Edgar Link pending
fvac-20200930_cal.xml Edgar Link unprocessable
fvac-20200930_def.xml Edgar Link unprocessable
fvac-20200930_htm.xml Edgar Link completed
fvac-20200930_lab.xml Edgar Link unprocessable
fvac-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending